Concepedia

CX Ma

CM

4

Publications

48

Citations

4

H-Index

2016

Active since

Affiliations

University of Alabama at Birmingham(Current)

Washington University in St. Louis

Baylor College of Medicine

CX Ma is an author at University of Alabama at Birmingham specializing in cancer therapeutics, breast cancer, and molecular oncology.

Top concepts

Publications per year

2016–2019

4

Publications

4

Abstract S6-05: A phase II trial of neoadjuvant palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with anastrozole for clinical stage 2 or 3 estrogen receptor positive HER2 negative (ER+HER2-) breast cancer (BC)

CX Ma, Fan Gao, Donald W. Northfelt et al. · Cancer Research · 2016 · 15 citations

, , +15

LncRNA TP73-AS1 promotes malignant progression of hepatoma by regulating microRNA-103.

CX Ma, Gao Wc, Lei Tian · PubMed · 2019 · 13 citations

Abstract PD3-07: Safety and efficacy results from a phase 1 study of DS-8201a in patients with HER2 expressing breast cancers

Shanu Modi, Junji Tsurutani, Shunji Takahashi et al. · Cancer Research · 2018 · 10 citations

Abstract OT3-05-11: Palbociclib after CDK inhibitor and endocrine therapy (PACE): A randomized phase II study of fulvestrant versus palbociclib plus fulvestrant, with and without avelumab, for CDK inhibitor pre-treated HR+/HER2- metastatic breast cancer

EL Mayer, SA Wander, MM Regan et al. · Cancer Research · 2018 · 10 citations

, , +15

Rows per page

1–4 of 4